Safety issues about nevirapine administration in HIV-infected pregnant women [5]

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 3, 2007, Pages 365-368

  Manfredi, Roberto ^a   Calza, Leonardo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; EFAVIRENZ; NEVIRAPINE;

ABNORMAL LABORATORY RESULT; ADULT; ADVERSE OUTCOME; AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LIVER TOXICITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; RASH; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; ANTI-HIV AGENTS; BILIRUBIN; CD4 LYMPHOCYTE COUNT; CONSUMER PRODUCT SAFETY; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS, TOXIC; HIV INFECTIONS; HUMANS; LIVER; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TRANSAMINASES;

EID: 34347342786     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318050d879     Document Type: Letter

References (21)

1. Office of AIDS Research Advisory Council (OARAC), US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 10, 2006. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed January 4, 2007.
2. Marazzi MC, Germano P, Liotta G, et al. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med. 2006;7:338-344.
3. Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral treatment with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet. 2004;363:1253-1263.
4. Bonjoch A, Paredes R, Domingo P, et al. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses. 2006;22:321-329.
5. Siegfried NL, Van Deventer PJ, Mahomed FA, et al. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Cochrane Database Syst Rev. 2006;2:CD004535.
6. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr. 2004;35:538-539.
7. Dieterich DT, Robinson PA, Love J, et al. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis. 2004;38(Suppl 2):S80-S89.
8. Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf. 2005;28:1075-1083.
9. FDA advisory on nevirapine. AIDS Treat News. 2005;409:7.
10. Manfredi R. HIV infection, antiretroviral therapy, and hepatic function. Emerging epidemiological, pathogenetic, and clinical issues, and their consequences on disease management. AIDS. 2003;17:2253-2256.
11. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr. 2004;36:772-776.
12. Joy S, Poi M, Hughes L, et al. Third-trimester maternal toxicity with nevirapine use in pregnancy. Obstet Gynecol. 2005;106:1032-1038.
13. Kappelhoff BS, Van Leth F, Robinson PA, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther. 2005;10:489-498.
14. Joao EC, Calvet GA, Menezes JA, et al. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol. 2006;194:199-202.
15. De Requeña DG, Jimenez-Nacher I, Soriano V. Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations. AIDS Res Hum Retroviruses. 2005;21:555-559.
16. Manfredi R, Calza L, Chiodo F. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated with efavirenz or nevirapine. HIV Clin Trials. 2005;6:302-311.
17. Ribera E, Rodriguez-Pardo D, Rubio M, et al. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naïve HIV-infected patients. Antivir Ther. 2005;10:605-614.
18. Sabbatani S, Manfredi R, Biagetti C, et al. Antiretroviral therapy in the real world. Population-based pharmacoeconomic analysis of administration of anti-HIV regimens to 990 patients. Clin Drug Invest. 2005;25:527-535.
19. Joao EC, Calvet GA, Menezes JA, et al. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol. 2006;194:199-202.
20. Manfredi R, Calza L. Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/μL. AIDS. 2006;20:2233-2236.
21. Timmermanns S, Tempelman C, Godfried MH, et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS. 2005;19:795-799.